177 related articles for article (PubMed ID: 14751837)
21. Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps.
Würl P; Bartel F; Meye A; Kappler M; Bache M; Schmidt H; Schönfelder M; Taubert H
Int J Oncol; 2002 May; 20(5):1087-93. PubMed ID: 11956608
[TBL] [Abstract][Full Text] [Related]
22. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
Chen L; Agrawal S; Zhou W; Zhang R; Chen J
Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
[TBL] [Abstract][Full Text] [Related]
23. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
Wang H; Hang J; Shi Z; Li M; Yu D; Kandimalla ER; Agrawal S; Zhang R
Int J Oncol; 2002 Jul; 21(1):73-80. PubMed ID: 12063552
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
Agrawal S; Kandimalla ER; Yu D; Hollister BA; Chen SF; Dexter DL; Alford TL; Hill B; Bailey KS; Bono CP; Knoerzer DL; Morton PA
Int J Oncol; 2001 May; 18(5):1061-9. PubMed ID: 11295057
[TBL] [Abstract][Full Text] [Related]
25. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
[TBL] [Abstract][Full Text] [Related]
26. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
Traidej M; Chen L; Yu D; Agrawal S; Chen J
Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
[TBL] [Abstract][Full Text] [Related]
27. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
28. The effect of Tc-99m-labeled MDM2 antisense oligonucleotide on gene expression in human breast cancer MCF-7 cells.
Zhao C; Fu P; Sheng Y; Li Z
J Exp Ther Oncol; 2007; 6(4):297-303. PubMed ID: 18038763
[TBL] [Abstract][Full Text] [Related]
29. p53-independent activities of MDM2 and their relevance to cancer therapy.
Zhang Z; Zhang R
Curr Cancer Drug Targets; 2005 Feb; 5(1):9-20. PubMed ID: 15720185
[TBL] [Abstract][Full Text] [Related]
30. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
31. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.
Mu Z; Hachem P; Agrawal S; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):336-43. PubMed ID: 14751501
[TBL] [Abstract][Full Text] [Related]
32. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.
Stoyanova R; Hachem P; Hensley H; Khor LY; Mu Z; Hammond ME; Agrawal S; Pollack A
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1151-60. PubMed ID: 17637390
[TBL] [Abstract][Full Text] [Related]
33. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Cho YS; Cho-Chung YS
Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
[TBL] [Abstract][Full Text] [Related]
34. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line.
Grünbaum U; Meye A; Bache M; Bartel F; Würl P; Schmidt H; Dunst J; Taubert H
Anticancer Res; 2001; 21(3B):2065-71. PubMed ID: 11497299
[TBL] [Abstract][Full Text] [Related]
35. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
36. MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides.
Bartel F; Harris LC; Würl P; Taubert H
Mol Cancer Res; 2004 Jan; 2(1):29-35. PubMed ID: 14757843
[TBL] [Abstract][Full Text] [Related]
37. Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer.
Cao C; Shinohara ET; Niermann KJ; Donnelly EF; Chen X; Hallahan DE; Lu B
Mol Cancer Ther; 2005 Aug; 4(8):1137-45. PubMed ID: 16093429
[TBL] [Abstract][Full Text] [Related]
38. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
39. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
